The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists.
ART calculator
POSEIDON criteria
assisted reproductive technology
blastocyst
low prognosis
oocyte
ovarian stimulation
poor ovarian response
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
06
2019
accepted:
06
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
12
12
2019
Statut:
epublish
Résumé
This article represents a viewpoint on the POSEIDON criteria by a group of clinicians and embryologists. Its primary objective is to contextualize the Poseidon criteria and their metric of success for the relevant Frontiers Research Topic "POSEIDON's Stratification of Low Prognosis Patients in ART: The WHY, the WHAT, and the HOW". "Low prognosis" relates with reduced oocyte number, which can be associated with low or sometimes a normal ovarian reserve and is aggravated by advanced female age. These aspects will ultimately affect the number of embryos generated and consequently, the cumulative live birth rate. The novel system relies on female age, ovarian reserve markers, ovarian sensitivity to exogenous gonadotropin, and the number of oocytes retrieved, which will both identify the patients with low prognosis and stratify such patients into one of four groups of women with "expected" or "unexpected" impaired ovarian response to exogenous gonadotropin stimulation. Furthermore, the POSEIDON group introduced a new measure of clinical success in ART, namely, the ability to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient. Using the POSEIDON criteria, the clinician can firstly identify and classify patients who have low prognosis in ART, and secondly, aim at designing an individualized treatment plan to maximize the chances of achieving the POSEIDON measure of success in each of the four low prognosis groups. The novel POSEIDON classification system is anticipated to improve counseling and management of low prognosis patients undergoing ART, with an expected positive effect on reproductive success and a reduction in the time to live birth.
Identifiants
pubmed: 31824427
doi: 10.3389/fendo.2019.00814
pmc: PMC6880663
doi:
Types de publication
Journal Article
Langues
eng
Pagination
814Informations de copyright
Copyright © 2019 Esteves, Alviggi, Humaidan, Fischer, Andersen, Conforti, Bühler, Sunkara, Polyzos, Galliano, Grynberg, Yarali, Özbek, Roque, Vuong, Banker, Rienzi, Vaiarelli, Cimadomo and Ubaldi.
Références
Hum Reprod. 2018 Jun 15;:null
pubmed: 29912374
Obstet Gynecol. 2014 Mar;123(3):719-21
pubmed: 24553169
Reprod Biomed Online. 2014 Dec;29(6):684-91
pubmed: 25444501
Front Endocrinol (Lausanne). 2019 Sep 11;10:614
pubmed: 31572298
Panminerva Med. 2019 Mar;61(1):11-23
pubmed: 30674180
Hum Reprod. 2016 Feb;31(2):370-6
pubmed: 26724797
Fertil Steril. 2017 Sep;108(3):393-406
pubmed: 28760517
Hum Reprod. 2018 Oct 1;33(10):1875-1882
pubmed: 30137360
Biomed Res Int. 2017;2017:5637923
pubmed: 28428962
Reprod Biol Endocrinol. 2010 Sep 16;8:112
pubmed: 20846363
Hum Reprod. 2017 Nov 1;32(11):2209-2217
pubmed: 29040519
Front Endocrinol (Lausanne). 2019 Jun 26;10:409
pubmed: 31293519
Hum Reprod. 2009 Dec;24(12):3127-35
pubmed: 19783833
Front Endocrinol (Lausanne). 2019 May 08;10:282
pubmed: 31139146
Hum Reprod. 2019 Jun 4;34(6):1030-1041
pubmed: 31125412
Front Endocrinol (Lausanne). 2019 Jun 27;10:387
pubmed: 31316461
Front Endocrinol (Lausanne). 2017 Jun 07;8:116
pubmed: 28638367
Reprod Biol Endocrinol. 2018 Mar 27;16(1):29
pubmed: 29587861
J Assist Reprod Genet. 2017 Jun;34(6):749-758
pubmed: 28321529
Fertil Steril. 2018 Apr;109(4):644-664
pubmed: 29653717
Reprod Biol Endocrinol. 2018 Mar 9;16(1):20
pubmed: 29523204
Fertil Steril. 2017 Nov;108(5):750-756
pubmed: 28923285
Fertil Steril. 2013 Jul;100(1):100-7.e1
pubmed: 23548942
Int J Qual Health Care. 2003 Dec;15(6):523-30
pubmed: 14660535
JAMA. 2015 Dec 22-29;314(24):2654-2662
pubmed: 26717030
Hum Reprod. 2018 May 1;33(5):982-983
pubmed: 29596626
Panminerva Med. 2019 Mar;61(1):3-10
pubmed: 29962186
Fertil Steril. 2018 Sep;110(4):661-670.e1
pubmed: 30196963
Front Endocrinol (Lausanne). 2018 Aug 17;9:461
pubmed: 30174650
Front Endocrinol (Lausanne). 2019 May 08;10:281
pubmed: 31139145
F1000Res. 2016 Dec 23;5:2911
pubmed: 28232864
Reprod Biol Endocrinol. 2019 Feb 6;17(1):18
pubmed: 30728019
Front Endocrinol (Lausanne). 2018 Jun 14;9:317
pubmed: 29963011
Fertil Steril. 2009 Mar;91(3):705-14
pubmed: 18321493
PLoS One. 2010 Jan 27;5(1):e8772
pubmed: 20111701
Reprod Biomed Online. 2006 Feb;12(2):221-33
pubmed: 16478591
Swiss Med Wkly. 2015 Feb 06;145:w14087
pubmed: 25668217
Fertil Steril. 2016 Jun;105(6):1452-3
pubmed: 26921622
Fertil Steril. 2017 Dec;108(6):961-972.e3
pubmed: 28985908
Front Endocrinol (Lausanne). 2018 Jun 29;9:327
pubmed: 30008696
Reprod Biomed Online. 2017 Apr;34(4):429-438
pubmed: 28189417
Fertil Steril. 2010 Oct;94(5):1647-51
pubmed: 20056216
Hum Reprod. 2011 Apr;26(4):827-33
pubmed: 21317152
Hum Reprod. 2011 Jul;26(7):1768-74
pubmed: 21558332
Front Endocrinol (Lausanne). 2019 Feb 28;10:99
pubmed: 30873117
BMJ. 2016 Nov 16;355:i5735
pubmed: 27852632
Fertil Steril. 2014 Oct;102(4):952-959.e15
pubmed: 25225072
Front Endocrinol (Lausanne). 2019 Apr 16;10:246
pubmed: 31040828
Hum Reprod Update. 2018 Sep 1;24(5):599-614
pubmed: 29924306
Reprod Biomed Online. 2012 Jun;24(6):614-20
pubmed: 22503277
Fertil Steril. 2016 Jun;105(6):1488-1495.e1
pubmed: 27020168
Front Endocrinol (Lausanne). 2018 Oct 17;9:589
pubmed: 30386293
Hum Reprod Update. 2019 Jan 1;25(1):2-14
pubmed: 30388233
Fertil Steril. 2017 Nov;108(5):777-783.e2
pubmed: 28987789
Hum Reprod Update. 2011 Jan-Feb;17(1):46-54
pubmed: 20667894